Biosimilars: Are they ready for primetime in the United States?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 8, 2011, Pages 934-943

  Hirsch, Bradford R ^a   Lyman, Gary H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biosimilars; Follow on biologics; Generics; Health policy; Myeloid growth factors; Subsequent entry biologics

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR; ERYTHROPOIETIN; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; INSULIN; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACCREDITATION; CANCER THERAPY; COLORECTAL CANCER; CONTINUING EDUCATION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOXICITY; FEBRILE NEUTROPENIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MEDICAL EDUCATION; PATIENT SAFETY; PHARMACEUTICS; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PURE RED CELL ANEMIA; REVIEW; UNITED STATES;

EID: 80051490700     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0076     Document Type: Review

References (46)

1. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008;300:1887-1896.
2. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006;11:341-346. (Pubitemid 44086880)
3. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-1391. (Pubitemid 39482857)
4. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005;20(Suppl 6):vi3-9.
5. Top 20 biologics 2009. Available at: http://www.pipelinereview.com/free- downloads/top-20-biologics-2009-rd-pipeline-news.pdf Accessed February 8, 2011.
6. European Medicines Agency. Guideline on similar biological medicinal products. 2005. Available at: www.ema.europa.eu/pdfs/human/biosimilar/043704en. pdf. Accessed February 9, 2011.
7. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2006. Available at: http:// www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003953.pdf. Accessed February 9, 2011.
8. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-419. (Pubitemid 351325660)
9. Grabowsk H. Patents and New Product Development in the Pharmaceutical and Biotechnology Industries. Duke University, Department of Economics. Available at: http://econ.duke.edu/Papers/Other/Grabowski/Patents.pdf. Accessed May 20, 2011.
10. Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood) 2006;25:1291-1301. (Pubitemid 44497628)
11. Mossinghoff GJ. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J 1999;54:187-194. (Pubitemid 29328042)
12. Center for Drug Evalation and Research. CDER guidance for industry: statistical approaches to establishing bioequivalence. 2001. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm070244.pdf. Accessed February 10, 2011.
13. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-1597.
14. Schellekens H, Ryff JC. 'Biogenerics': the off-patent biotech products. Trends Pharmacol Sci 2002;23:119-121.
15. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462. (Pubitemid 37361488)
16. Hesse F, Wagner R. Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol 2000;18:173-180. (Pubitemid 30171336)
17. Mullard A. Hearing shines spotlight on biosimilar controversies. Nat Rev Drug Discov 2010;9:905-906.
18. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346-2353. (Pubitemid 41623396)
19. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-780.
20. European Medicines Agency. Pharmacovigilance - Medicinal products for human use and veterinary medicinal products. 2004. Available at: http://ec.europa.eu/health/documents/eudralex/vol-9/index-en.htm. Accessed February 10, 2011.
21. European Medicines Agency. Guidance on similar medicinal products containing recombinant erythropoietins. 2006. Available at: http://www.ema. europa.eu/pdfs/human/biosimilar/9452605en.pdf. Accessed February 10. 2011.
22. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (revision). 2009. Available at: http://www.ema.europa.eu/pdfs/ human/biosimilar/30163608endraft.pdf. Accessed February 10, 2011.
23. Euroepan Medicines Agency. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. 2006. Available at: http://www.tga.gov.au/docs/pdf/euguide/bmwp/3132905en.pdf. Accessed February 10, 2011.
24. European Medicines Agency. Guidance on similar medicinal products of recombinant human soluble insulin. 2006. Available at: http://www.ema.europa.eu/ pdfs/human/biosimilar/3277505en.pdf. Accessed February 10, 2011.
25. European Medicines Agency. Questions and Answers on biosimilar medicines (similar biological medicinal products). 2008. Available at: http://www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf. Accessed February 10, 2011.
26. European Medicines Agency. European public assements reports: cancer. 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/ medicines/landing/epar-search.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125&searchTab=&alreadyLoaded=true&status= Authorised&status=Withdrawn&status=Suspended&status= Refused&keyword=Enter+keywords&searchType=name&taxonomyPath= Diseases&treeNumber=¤tCategory=Cancer&searchGenericType= generics. Accessed February 10, 2011.
27. Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009;1:394-416.
28. European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Insulin Human Rapid Marvel, Insulin Human Long Marvel, Insulin Human 30/70 Mix Marvel. 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2009/11/ WC500015341.pdf. Accessed February 10, 2011.
29. European Medicines Agency. Questions and answers on recommendation for the refusal of the marketing authorisation for Biferonex. 2009. Available at: http://www.ema.europa.eu/pdfs/human/opinion/BiferonexQ&A-9112009en.pdf. Accessed February 10, 2011.
30. Grabowski H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 2008;7:479-488. (Pubitemid 351767116)
31. Hodgson J. WHO guidelines presage US biosimilars legislation? Nat Biotechnol 2009;27:963-965.
32. European Generic Medicines Association. Vision 2015: the EGA's thoughts on how to improve the legal and regulatory framework for generic and biosimilar medicines. 2010. Available at: http://www.egagenerics.com/doc/EGA-Vision-2015. pdf. Accessed February 10, 2011.
33. Oldham T. Strategies for entering the biosimilar market. In: Oldham T, ed. Biosimilars-Evolution or Revolution. London, England: Biopharm Knowledge Publishing; 2006.
34. Ledford H. 'Biosimilar' drugs poised to penetrate market. Nature 2010;468:18-19.
35. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw 2009;7:64-83.
36. Orciuolo E, Buda G, Marturano E, et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res 2011;35:899-903.
37. Kim IH, Park SK, Suh OK, Oh JM. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin 2003;19:753-759. (Pubitemid 37466146)
38. Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474-479. (Pubitemid 27345130)
39. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-2295. (Pubitemid 350246613)
40. Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-1104.
41. Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504-511.
42. Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:927-933.
43. Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:971-978.
44. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 2010;38:557-566.
45. Schellekens H. Assessing the bioequivalence of biosimilars the Retacrit case. Drug Discov Today 2009;14:495-499.
46. DiMartino LD, Curtis LH, Williams RL, et al. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food Drug Law J 2008;63:891-900.